Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

CXCR4 is highly expressed at the tumor front but not in the center of prostate cancers.

Delongchamps NB, Beuvon F, Mathieu JR, Delmas S, Metzger I, Prats H, Cabon F.

World J Urol. 2015 Feb;33(2):281-7. doi: 10.1007/s00345-014-1299-0. Epub 2014 Apr 19.

PMID:
24748552
2.

Risk of hormone escape in a human prostate cancer model depends on therapy modalities and can be reduced by tyrosine kinase inhibitors.

Guyader C, Céraline J, Gravier E, Morin A, Michel S, Erdmann E, de Pinieux G, Cabon F, Bergerat JP, Poupon MF, Oudard S.

PLoS One. 2012;7(8):e42252. doi: 10.1371/journal.pone.0042252. Epub 2012 Aug 6.

3.

Thrombospondin-1 triggers cell migration and development of advanced prostate tumors.

Firlej V, Mathieu JR, Gilbert C, Lemonnier L, Nakhlé J, Gallou-Kabani C, Guarmit B, Morin A, Prevarskaya N, Delongchamps NB, Cabon F.

Cancer Res. 2011 Dec 15;71(24):7649-58. doi: 10.1158/0008-5472.CAN-11-0833. Epub 2011 Oct 28.

4.

Identification of CAD as an androgen receptor interactant and an early marker of prostate tumor recurrence.

Morin A, Fritsch L, Mathieu JR, Gilbert C, Guarmit B, Firlej V, Gallou-Kabani C, Vieillefond A, Delongchamps NB, Cabon F.

FASEB J. 2012 Jan;26(1):460-7. doi: 10.1096/fj.11-191296. Epub 2011 Oct 7.

PMID:
21982950
5.

Role of cationic channel TRPV2 in promoting prostate cancer migration and progression to androgen resistance.

Monet M, Lehen'kyi V, Gackiere F, Firlej V, Vandenberghe M, Roudbaraki M, Gkika D, Pourtier A, Bidaux G, Slomianny C, Delcourt P, Rassendren F, Bergerat JP, Ceraline J, Cabon F, Humez S, Prevarskaya N.

Cancer Res. 2010 Feb 1;70(3):1225-35. doi: 10.1158/0008-5472.CAN-09-2205. Epub 2010 Jan 26.

6.

Systemic delivery and quantification of unformulated interfering RNAs in vivo.

Morin A, Gallou-Kabani C, Mathieu JR, Cabon F.

Curr Top Med Chem. 2009;9(12):1117-29. Review.

PMID:
19860712
7.

Interference with netrin-1 and tumor cell death in non-small cell lung cancer.

Delloye-Bourgeois C, Brambilla E, Coissieux MM, Guenebeaud C, Pedeux R, Firlej V, Cabon F, Brambilla C, Mehlen P, Bernet A.

J Natl Cancer Inst. 2009 Feb 18;101(4):237-47. doi: 10.1093/jnci/djn491. Epub 2009 Feb 10.

PMID:
19211441
8.

SIRNA-directed in vivo silencing of androgen receptor inhibits the growth of castration-resistant prostate carcinomas.

Compagno D, Merle C, Morin A, Gilbert C, Mathieu JR, Bozec A, Mauduit C, Benahmed M, Cabon F.

PLoS One. 2007 Oct 10;2(10):e1006.

9.

Testosterone regulates FGF-2 expression during testis maturation by an IRES-dependent translational mechanism.

Gonzalez-Herrera IG, Prado-Lourenco L, Pileur F, Conte C, Morin A, Cabon F, Prats H, Vagner S, Bayard F, Audigier S, Prats AC.

FASEB J. 2006 Mar;20(3):476-8. Epub 2006 Jan 19. Erratum in: FASEB J. 2006 Jul;20(9):1573-4.

PMID:
16423876
10.

IRES-dependent regulation of FGF-2 mRNA translation in pathophysiological conditions in the mouse.

Gonzalez-Herrera IG, Prado-Lourenco L, Teshima-Kondo S, Kondo K, Cabon F, Arnal JF, Bayard F, Prats AC.

Biochem Soc Trans. 2006 Feb;34(Pt 1):17-21. Review.

PMID:
16246170
11.

Evidence for specific TRPM8 expression in human prostate secretory epithelial cells: functional androgen receptor requirement.

Bidaux G, Roudbaraki M, Merle C, Crépin A, Delcourt P, Slomianny C, Thebault S, Bonnal JL, Benahmed M, Cabon F, Mauroy B, Prevarskaya N.

Endocr Relat Cancer. 2005 Jun;12(2):367-82.

PMID:
15947109
12.

Human breast tumors override the antiangiogenic effect of stromal thrombospondin-1 in vivo.

Fontana A, Filleur S, Guglielmi J, Frappart L, Bruno-Bossio G, Boissier S, Cabon F, Clézardin P.

Int J Cancer. 2005 Sep 20;116(5):686-91.

13.

Androgens repress the expression of the angiogenesis inhibitor thrombospondin-1 in normal and neoplastic prostate.

Colombel M, Filleur S, Fournier P, Merle C, Guglielmi J, Courtin A, Degeorges A, Serre CM, Bouvier R, Clézardin P, Cabon F.

Cancer Res. 2005 Jan 1;65(1):300-8.

14.

A Suv39h-dependent mechanism for silencing S-phase genes in differentiating but not in cycling cells.

Ait-Si-Ali S, Guasconi V, Fritsch L, Yahi H, Sekhri R, Naguibneva I, Robin P, Cabon F, Polesskaya A, Harel-Bellan A.

EMBO J. 2004 Feb 11;23(3):605-15. Epub 2004 Feb 5.

15.

SiRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth.

Filleur S, Courtin A, Ait-Si-Ali S, Guglielmi J, Merle C, Harel-Bellan A, Clézardin P, Cabon F.

Cancer Res. 2003 Jul 15;63(14):3919-22.

16.

Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats.

Fournier P, Boissier S, Filleur S, Guglielmi J, Cabon F, Colombel M, Clézardin P.

Cancer Res. 2002 Nov 15;62(22):6538-44.

17.

In vivo mechanisms by which tumors producing thrombospondin 1 bypass its inhibitory effects.

Filleur S, Volpert OV, Degeorges A, Voland C, Reiher F, Clézardin P, Bouck N, Cabon F.

Genes Dev. 2001 Jun 1;15(11):1373-82.

18.

CBP/p300 histone acetyl-transferase activity is important for the G1/S transition.

Ait-Si-Ali S, Polesskaya A, Filleur S, Ferreira R, Duquet A, Robin P, Vervish A, Trouche D, Cabon F, Harel-Bellan A.

Oncogene. 2000 May 11;19(20):2430-7.

19.

The Wilms' tumor gene product represses the transcription of thrombospondin 1 in response to overexpression of c-Jun.

Dejong V, Degeorges A, Filleur S, Ait-Si-Ali S, Mettouchi A, Bornstein P, Binétruy B, Cabon F.

Oncogene. 1999 May 20;18(20):3143-51.

20.

The c-Jun-induced transformation process involves complex regulation of tenascin-C expression.

Mettouchi A, Cabon F, Montreau N, Dejong V, Vernier P, Gherzi R, Mercier G, Binétruy B.

Mol Cell Biol. 1997 Jun;17(6):3202-9.

21.

Peripheral myelin protein-22 is expressed in rat and mouse brain and spinal cord motoneurons.

Parmantier E, Cabon F, Braun C, D'Urso D, Müller HW, Zalc B.

Eur J Neurosci. 1995 May 1;7(5):1080-8.

PMID:
7613613
22.

HIV-1 envelope glycoprotein gp120 does not bind to galactosylceramide-expressing rat oligodendrocytes.

Parmantier E, Monge M, Yagello M, Cabon F, Demerens C, Gluckman JC, Zalc B.

Virology. 1995 Feb 1;206(2):1084-91.

23.

Hereditary neuralgic amyotrophy and hereditary neuropathy with liability to pressure palsies: two distinct clinical, electrophysiologic, and genetic entities.

Gouider R, LeGuern E, Emile J, Tardieu S, Cabon F, Samid M, Weissenbach J, Agid Y, Bouche P, Brice A.

Neurology. 1994 Dec;44(12):2250-2.

PMID:
7991107
24.

SPARC and thrombospondin genes are repressed by the c-jun oncogene in rat embryo fibroblasts.

Mettouchi A, Cabon F, Montreau N, Vernier P, Mercier G, Blangy D, Tricoire H, Vigier P, Binétruy B.

EMBO J. 1994 Dec 1;13(23):5668-78.

25.

Glycerophosphorylcholine phosphocholine phosphodiesterase activity during the differentiation of glial progenitor cells.

Monge M, Yuan J, Cabon F, Zalc B, Kanfer JN.

J Neurosci Res. 1993 Nov 1;36(4):441-5.

PMID:
8271316
26.

The E. coli envY gene encodes a high affinity opioid binding site.

Cabon F, Morser J, Parmantier E, Solly SK, Pham-Dinh D, Zalc B.

Neurochem Res. 1993 Jul;18(7):795-800.

PMID:
8396214
27.

The proximal region of the MBP gene promoter is sufficient to induce oligodendroglial-specific expression in transgenic mice.

Goujet-Zalc C, Babinet C, Monge M, Timsit S, Cabon F, Gansmüller A, Miura M, Sanchez M, Pournin S, Mikoshiba K, Zalc B.

Eur J Neurosci. 1993 Jun 1;5(6):624-32.

PMID:
7505168
28.

Regional and developmental variations of GFAP and actin mRNA levels in the CNS of jimpy and shiverer mutant mice.

Chen H, Cabon F, Sun P, Parmantier E, Dupouey P, Jacque C, Zalc B.

J Mol Neurosci. 1993 Summer;4(2):89-96.

PMID:
8217522
29.

Developmental expression of glial fibrillary acidic protein and actin-encoding messages in quaking and control mice.

Chen H, Sun P, Parmantier E, Cabon F, Dupouey P, Zalc B, Jacque C.

Dev Neurosci. 1992;14(5-6):351-6.

PMID:
1306160
30.

Pharmacological and molecular properties of opioid binding sites synthesized in a cell-free translation system.

Cabon F, Cupo A, Ruiz-Gayo M, Baumann NA, Zalc B.

J Neurosci Res. 1990 Jun;26(2):242-50.

PMID:
2164109
31.

Cell-free synthesis of opiate binding sites.

Cabon F, Rhyner T, Blanot F, Goujet-Zalc C, Mallet J, Zalc B.

Neurochem Int. 1987;11(2):219-21.

PMID:
20501164

Supplemental Content

Support Center